inositol has been researched along with Age-Related Memory Disorders in 12 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Excerpt | Relevance | Reference |
---|---|---|
"Peripheral hyperglycemia was associated with significant increases in brain sorbitol (7." | 3.74 | Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory. ( Chong, L; Diamond, DM; Hanna, S; Malone, JI; Mervis, RF; Park, CR; Saporta, S, 2008) |
"Epilepsy is a severe neurological disease characterized by spontaneous recurrent seizures (SRS)." | 1.72 | Myo-Inositol Limits Kainic Acid-Induced Epileptogenesis in Rats. ( Burjanadze, M; Dashniani, M; Gamkrelidze, G; Kandashvili, M; Kokaia, M; Lagani, V; Lepsveridze, E; Lordkipanidze, T; Solomonia, R; Tsverava, L, 2022) |
"Despite progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged." | 1.33 | Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. ( Cleary, JP; Hofmeister, J; Lesne, S; Mehta, T; O'Hare, E; Selkoe, DJ; Townsend, M; Walsh, DM, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 6 (50.00) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Kandashvili, M | 1 |
Gamkrelidze, G | 1 |
Tsverava, L | 1 |
Lordkipanidze, T | 1 |
Lepsveridze, E | 1 |
Lagani, V | 1 |
Burjanadze, M | 1 |
Dashniani, M | 1 |
Kokaia, M | 1 |
Solomonia, R | 1 |
Shan, Y | 1 |
Jia, Y | 1 |
Zhong, S | 1 |
Li, X | 1 |
Zhao, H | 1 |
Chen, J | 1 |
Lu, Q | 1 |
Zhang, L | 1 |
Li, Z | 1 |
Lai, S | 1 |
Wang, Y | 1 |
Lee, BH | 1 |
Lee, CC | 1 |
Wu, SC | 1 |
Mazgaj, R | 1 |
Tal, A | 1 |
Goetz, R | 1 |
Lazar, M | 1 |
Rothman, K | 1 |
Messinger, JW | 1 |
Malaspina, D | 1 |
Gonen, O | 1 |
Malone, JI | 1 |
Hanna, S | 1 |
Saporta, S | 1 |
Mervis, RF | 1 |
Park, CR | 1 |
Chong, L | 1 |
Diamond, DM | 1 |
Weiss, U | 1 |
Bacher, R | 1 |
Vonbank, H | 1 |
Kemmler, G | 1 |
Lingg, A | 1 |
Marksteiner, J | 1 |
Frederick, BD | 1 |
Lyoo, IK | 1 |
Satlin, A | 1 |
Ahn, KH | 1 |
Kim, MJ | 1 |
Yurgelun-Todd, DA | 1 |
Cohen, BM | 1 |
Renshaw, PF | 1 |
Metastasio, A | 1 |
Rinaldi, P | 1 |
Tarducci, R | 2 |
Mariani, E | 1 |
Feliziani, FT | 1 |
Cherubini, A | 1 |
Pelliccioli, GP | 2 |
Gobbi, G | 2 |
Senin, U | 2 |
Mecocci, P | 1 |
Townsend, M | 1 |
Cleary, JP | 1 |
Mehta, T | 1 |
Hofmeister, J | 1 |
Lesne, S | 1 |
O'Hare, E | 1 |
Walsh, DM | 1 |
Selkoe, DJ | 1 |
Parnetti, L | 1 |
Lowenthal, DT | 1 |
Presciutti, O | 1 |
Palumbo, R | 1 |
Chiarini, P | 1 |
Palumbo, B | 1 |
Lin, A | 1 |
Nguy, CH | 1 |
Shic, F | 1 |
Ross, BD | 1 |
Ritschel, WA | 1 |
Wagensonner, D | 1 |
Heringer, EA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
2 trials available for inositol and Age-Related Memory Disorders
Article | Year |
---|---|
Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Aged; Aspartic Acid; Brain; Brain Chemistry; Choline; Creatine; Dimethy | 2001 |
[Statistical evaluation of the effect of 3 stimulants of cellular metabolism].
Topics: Adult; Aged; Aminobutyrates; Ascorbic Acid; Attention; Calcium; Depression; Emotions; Fatigue; Feedi | 1970 |
10 other studies available for inositol and Age-Related Memory Disorders
Article | Year |
---|---|
Myo-Inositol Limits Kainic Acid-Induced Epileptogenesis in Rats.
Topics: Animals; Antinematodal Agents; Disease Models, Animal; Epilepsy; Inositol; Kainic Acid; Male; Memory | 2022 |
Correlations between working memory impairment and neurometabolites of prefrontal cortex and lenticular nucleus in patients with major depressive disorder.
Topics: Adult; Aspartic Acid; Case-Control Studies; Choline; Corpus Striatum; Creatine; Depressive Disorder, | 2018 |
Ice plant (Mesembryanthemum crystallinum) improves hyperglycaemia and memory impairments in a Wistar rat model of streptozotocin-induced diabetes.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Blood Glucose; Brain; Cholinesterase Inhibitors; | 2014 |
Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia.
Topics: Adult; Aging; Aspartic Acid; Creatine; Female; Gliosis; Gyrus Cinguli; Humans; Inositol; Intelligenc | 2016 |
Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory.
Topics: Animals; Brain Chemistry; Cerebral Cortex; Dendrites; Dendritic Spines; Diabetes Mellitus, Experimen | 2008 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Anim | 2006 |
1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Stud | 1996 |